Editorial
Accepted on 14 Feb 2025
Editorial: Novel Therapeutic Target and Drug Discovery for Neurological Diseases, Volume II
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1566950
Type at least 3 characters
2,315 articles
Articles
Original Research
Published on 14 Feb 2025
Methamphetamine self-administration causes neuronal dysfunction in rat medial prefrontal cortex in a sex-specific and withdrawal time-dependent manner
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1527795
- 169 views
Original Research
Published on 14 Feb 2025
The effect of cannabinoid type Ⅱ receptor on the excitability of substantia nigra dopaminergic neurons
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1522210
- 137 views
Original Research
Published on 13 Feb 2025
Medroxyprogesterone promotes neuronal survival after cerebral ischemic stroke by inhibiting PARthanatos
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1487436
- 153 views
Original Research
Accepted on 12 Feb 2025
Zingerone Alleviates Inflammatory Pain by Reducing The Intrinsic Excitability of Anterior Cingulate Cortex Neurons in a Mice Model
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1543594
Original Research
Accepted on 12 Feb 2025
Evaluation of the Neuroprotective Potential of Benzylidene Digoxin 15 (BD-15) against Oxidative Stress in a Neuroinflammation Models Induced by Lipopolysaccharide (LPS) and on neuronal differentiation of hippocampal neural precursor cells
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1537720
Original Research
Accepted on 12 Feb 2025
Vortioxetine alleviates motor, cognitive and emotional disorders in post-stroke rats by regulating the TLR-2/NF-κB pathway
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1555079
Original Research
Accepted on 11 Feb 2025
Randomized crossover clinical studies to assess abuse liability and nicotine pharmacokinetics of Velo oral nicotine pouches
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1547073
Original Research
Accepted on 10 Feb 2025
Marked differences in the effects of levetiracetam and its analogue brivaracetam on microglial, astrocytic-and neuronal density in the rat model of kainic acid-induced temporal lobe epilepsy
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1553545
Editorial
Published on 10 Feb 2025
Editorial: The mechanistic investigation and emerging therapies for Friedreich’s ataxia
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1560808
- 328 views
Mini Review
Accepted on 07 Feb 2025
Innovative therapeutic strategies using ADHD medications tailored to the behavioral characteristics of patients with chronic pain
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1500313
- 124 views
Systematic Review
Accepted on 06 Feb 2025
Clinical implications of fracture severity risk with pioglitazone: A systematic review and meta-analysis of clinical randomized trials
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1357309
Review
Accepted on 05 Feb 2025
World No-Tobacco: Effects of Second-Hand Smoke (SHS) and vapors on the Developing and Adult Brain
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1466332
Systematic Review
Accepted on 04 Feb 2025
Efficacy and safety of pharmacological and non-pharmacological therapies in Lennox-Gastaut syndrome: a systematic review and network meta-analysis
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1522543
Review
Accepted on 04 Feb 2025
Ferroptosis, pathogenesis and therapy in AS co-depression disease Authors：
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1516601
Review
Accepted on 04 Feb 2025
Using estrogen and progesterone to treat Premenstrual Dysphoric Disorder, Postnatal Depression and Menopausal Depression
in Neuropharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1528544